Product Details

Artesunate + Mefloquine Tablets BP 300 mg deliver a high-quality combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose combination manages uncomplicated Plasmodium falciparum malaria, combining fast-acting and long-acting antimalarial mechanisms in a single tablet.

The tablets combine:

• Artesunate, an artemisinin derivative that rapidly reduces parasite biomass by generating free radicals that damage the malaria parasite’s membrane structures, and
• Mefloquine, a quinoline-methanol antimalarial that clears residual parasites and prevents recrudescence by interfering with parasite heme detoxification, providing longer-acting protection.

Doctors and health programs commonly prescribe this combination as an artemisinin-based combination therapy (ACT) for uncomplicated falciparum malaria, particularly in regions with chloroquine-resistant strains. Hospitals, clinics, and pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant combination therapy
• Treats uncomplicated Plasmodium falciparum malaria
• Delivers fast-acting and long-acting antimalarial action
• Accurate 300 mg dosage per tablet
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, clinical, and pharmacy use